Subcutaneous Epcoritamab plus R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

被引：19

作者：

Abrisqueta, Pau ^{[1
]}

Cordoba, Raul ^{[2
]}

Falchi, Lorenzo ^{[3
]}

de Vos, Sven ^{[4
]}

Nijland, Marcel ^{[5
,6
]}

Offner, Fritz ^{[7
]}

Wu, Jun ^{[8
]}

Bykhovski, Irina ^{[9
]}

Wang, Liwei ^{[9
]}

Rana, Ali ^{[9
]}

Phillips, Tycel ^{[10
]}

机构：

[1] Hosp Univ Vall dHebron, Barcelona, Spain

[2] Fdn Jimenez Diaz Univ Hosp, Hlth Res Inst IIS FJD, Dept Hematol, Lymphoma Unit, Madrid, Spain

[3] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, 1275 York Ave, New York, NY 10021 USA

[4] Ronald Reagan Univ Calif Los Angeles Med Ctr, Los Angeles, CA USA

[5] Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[6] Univ Groningen, Groningen, Netherlands

[7] Univ Ziekenhuis Gent, Ghent, Belgium

[8] AbbVie, N Chicago, IL 60064 USA

[9] Genmab, Princeton, NJ USA

[10] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA

来源：

关键词：

D O I：

10.1182/blood-2022-158278

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1068 / 1069

页数：2